6533b829fe1ef96bd1289a58
RESEARCH PRODUCT
AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine.
Camille VerryAwatef AllouchCarolyn J. AndersonOlivier TillementCyrus ChargariNathalie MignetBenoit LarratMarc JanierJacqueline Sidi-boumedineKevin M. PrisePeter FriesBich-thuy DoanErika PorcelFabien RossettiJacques BalossoMarie-caline AbadjianDominique ArdailFrédéric BoschettiYannick CrémillieuxAlexandre DetappeClaire Rodriguez-lafrasseRoss BerbecoMarie-thérèse AloySébastien MériauxVu Long TranEmmanuel L. BarbierSandrine LacombeSandrine DufortMatteo MartiniAndreas MüllerEric DeutschKarl T. ButterworthEmmanuelle Canet-soulasGéraldine Le DucFranck DenatGoran AngelovskiGuillaume BortCéline FrochotJean-luc PerfettiniEloise ThomasStéphane RouxTristan DoussineauMuriel Barberi-heyobMichael J. EvansFrançois LuxCharles TruilletStephen J. McmahonPenelope Bouziotissubject
Radiation-Sensitizing AgentsGadoliniummedicine.medical_treatmentGadolinium02 engineering and technologyReview ArticlePharmacologyTheranostic NanomedicineMice0302 clinical medicineMelanomaBrain NeoplasmsMelanomaGeneral Medicine[CHIM.MATE]Chemical Sciences/Material chemistry[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences021001 nanoscience & nanotechnology3. Good health[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciencesNuclear Medicine & Medical ImagingRadiology Nuclear Medicine and imagingHead and Neck Neoplasms030220 oncology & carcinogenesisToxicity/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being[SDV.IB]Life Sciences [q-bio]/Bioengineering0210 nano-technologyClinical Scienceschemistry.chemical_element[SDV.CAN]Life Sciences [q-bio]/CancerEnhanced permeability and retention effect03 medical and health sciences/dk/atira/pure/subjectarea/asjc/2700/2741SDG 3 - Good Health and Well-being[SDV.CAN] Life Sciences [q-bio]/CancerIn vivo[CHIM.ANAL]Chemical Sciences/Analytical chemistrymedicineAnimalsHumansRadiology Nuclear Medicine and imaging[SDV.IB] Life Sciences [q-bio]/Bioengineeringbusiness.industryCancermedicine.diseaseRadiation therapyClinical trialchemistryNanoparticlesbusinessForecastingdescription
International audience; AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been observed with different types of irradiations in vitro and in vivo on a large number of cancer types (brain, lung, melanoma, head and neck…). The review concludes with the second generation of AGuIX nanoparticles and the first preliminary results on human.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-01-01 |